| Code | CSB-RA835695MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to galegenimab, designed for research targeting HTRA1 (High Temperature Requirement A Serine Peptidase 1). HTRA1 is a secreted serine protease that degrades extracellular matrix proteins and regulates transforming growth factor-beta (TGF-β) signaling pathways. This enzyme plays critical roles in cellular homeostasis, protein quality control, and tissue remodeling. Dysregulation of HTRA1 has been implicated in several pathological conditions, including age-related macular degeneration (AMD), cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL), osteoarthritis, and various cancers. Elevated HTRA1 expression contributes to pathological angiogenesis and extracellular matrix degradation in these diseases.
Galegenimab is a reference therapeutic antibody that selectively inhibits HTRA1 enzymatic activity, representing a promising approach for treating HTRA1-mediated disorders. This biosimilar antibody provides researchers with a valuable tool for investigating HTRA1 biology, exploring disease mechanisms, validating therapeutic targets, and conducting preclinical studies in ophthalmology, neurology, and oncology research.
There are currently no reviews for this product.